Description: Vaxil Bio Ltd., formerly Emerge Resources Corp., is an immune-oncology biotechnology company. The Company is engaged in research and development of ImMucin vaccine to treat cancer. The Company develops immunotherapies, including neoantigen peptide products, and antibodies to treat cancer and infectious diseases. The Company offers VaxHit platform, which allows for identification, isolation and production of specific antigen-based immunotherapy products. The Company offers its products from VaxHit technology, which uses the signal peptide (SP) domain in selected targets as core antigens. The Company's product, ImMucin, which has received orphan drug status and designed for the treatment of multiple myeloma (MM) cancer. The Company's ImMucin is in Phase I clinical trial to treat antigen specific immunotherapies; SPmAb2 and SPmAb6 are in pre-clinical stage to treat SP specific antibodies, and MTbuVax is in pre-clinical stage to treat anti-infectives.
Home Page: www.vaxil-bio.com
VXL Technical Analysis
3400 One First Canadian Place
Toronto,
ON
M5X 1A4
Canada
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Gadi Levin B.Com., C.A., CPA, M.B.A., MBA | Chairman & CFO |
| Dr. Yuval Avnir Ph.D. | Head of R&D & CEO |
| Dr. Riva Kovjazin M.D. | Sr. Scientist & Member of Scientific Advisory Board |
Exchange: V
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.1041 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |